Literature DB >> 23908682

Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor.

Matthias Hofmann1, Ralph Pflanzer, Nadja Nicole Zoller, August Bernd, Roland Kaufmann, Diamant Thaci, Jurgen Bereiter-Hahn, Satoshi Hirohata, Stefan Kippenberger.   

Abstract

Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.

Entities:  

Year:  2013        PMID: 23908682      PMCID: PMC3730014          DOI: 10.1593/tlo.13274

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  39 in total

Review 1.  Structure, expression and receptor-binding properties of novel vascular endothelial growth factors.

Authors:  U Eriksson; K Alitalo
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

2.  Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia.

Authors:  A Lymboussaki; B Olofsson; U Eriksson; K Alitalo
Journal:  Circ Res       Date:  1999-11-26       Impact factor: 17.367

Review 3.  Barriers to drug delivery in solid tumors.

Authors:  R K Jain
Journal:  Sci Am       Date:  1994-07       Impact factor: 2.142

4.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.

Authors:  A J Leu; D A Berk; A Lymboussaki; K Alitalo; R K Jain
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

5.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

Review 6.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

7.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

8.  Interstitial fluid pressure in DMBA-induced rat mammary tumours.

Authors:  H Wiig; E Tveit; R Hultborn; R K Reed; L Weiss
Journal:  Scand J Clin Lab Invest       Date:  1982-04       Impact factor: 1.713

9.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.

Authors:  Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

10.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.

Authors:  E Kukk; A Lymboussaki; S Taira; A Kaipainen; M Jeltsch; V Joukov; K Alitalo
Journal:  Development       Date:  1996-12       Impact factor: 6.868

View more
  7 in total

1.  Characterization of internodal collecting lymphatic vessel function after surgical removal of an axillary lymph node in mice.

Authors:  Sunkuk Kwon; Roger E Price
Journal:  Biomed Opt Express       Date:  2016-03-03       Impact factor: 3.732

Review 2.  Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer.

Authors:  Amanda W Lund; Terry R Medler; Sancy A Leachman; Lisa M Coussens
Journal:  Cancer Discov       Date:  2015-11-09       Impact factor: 39.397

3.  Tumor interstitial fluid pressure-a link between tumor hypoxia, microvascular density, and lymph node metastasis.

Authors:  Einar K Rofstad; Kanthi Galappathi; Berit S Mathiesen
Journal:  Neoplasia       Date:  2014-07       Impact factor: 5.715

4.  Regulation of expression level of fms-like tyrosine kinase-4 is related to osteoclast differentiation.

Authors:  Yi Zhu; Yuan Wu; Yu Liang; Wenfu Tan; Zhuoran Liu; Jianhua Xiao
Journal:  Arch Med Sci       Date:  2015-11-30       Impact factor: 3.318

5.  Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis.

Authors:  Keiichi Asano; Courtney M Nelson; Sumeda Nandadasa; Noriko Aramaki-Hattori; Daniel J Lindner; Tyler Alban; Junko Inagaki; Takashi Ohtsuki; Toshitaka Oohashi; Suneel S Apte; Satoshi Hirohata
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

6.  The Role of Interstitial Fluid Pressure in Cerebral Porous Biomaterial Integration.

Authors:  Fabien Bonini; Sébastien Mosser; Flavio Maurizio Mor; Anissa Boutabla; Patrick Burch; Amélie Béduer; Adrien Roux; Thomas Braschler
Journal:  Brain Sci       Date:  2022-03-22

Review 7.  Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines.

Authors:  Yadollah Omidi; Jaleh Barar
Journal:  Bioimpacts       Date:  2014-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.